I would guess the short thesis is MRK approval? seems like a hazardous play for a cash rich bio with very good prospects for their next gen...which isn't going to read out tomorrow but a buyout w a CVR pending ph 3 results could happen any day
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.